- December 13, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
ADVERTISEMENT
Brand Name :
Ultiva
Synonyms :
remifentanil
Class :
Opioids (narcotic analgesics)
Dosage Forms & Strengths
Powder for injection
(1mg, 2mg, 3mg) per vial
Indicated for Anesthesia Induction
0.5-1 mcg/kg per minute IV; may be increased up to 1 mcg/kg per minute
Indicated for Anesthesia Maintenance
0.25-0.5 mcg/kg per minute; and for every 2-5 minutes 0.5-1 mcg/kg bolus in response to light anaesthesia
Indicated for Conscious Analgesia
1 mcg/kg IV bolus, followed by 0.05-0.2 mcg/kg per minute IV
Indicated for Post-Operative Period :
0.025-0.2 mcg/kg per minute IV
Dosage Forms & Strengths
Powder for injection
(1mg, 2mg, 3mg) per vial
Indicated for Maintenance:
Age: 2 months
0.4 mcg/kg per minute IV with Nitrous Oxide
Age: 1-12 years
0.25 mcg/kg per minute IV halothane, sevoflurane, & isoflurane
0.05-1.3 mcg/kg per minute IV, with a supplemental dose of 1 mcg/kg given over 30-60 secs IV
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may have an increased CNS depressant effect when combined with opioid agonists
may enhance the serum concentration
may increase the CNS depressant effect
may increase the CNS depressant effect of CNS depressants
acrivastine and pseudoephedrine
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increased CNS depressive effect when combined with opioid agonists
may have an increasingly adverse effect when combined with alvimopan
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS Depressants
may increase the adverse effect of Monoamine Oxidase Inhibitors
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the efficacy of other opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
may decrease the analgesic effect of opioids
may have an increased constipating effect when combined with eluxadoline
may decrease the therapeutic effect when combined with opioid agonists
methylnaltrexone: they may increase the adverse effect of opioid antagonists
samidorphan: they may decrease the therapeutic effect of opioid agonists
may decrease the therapeutic effect of Nalmefene
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may enhance the adverse/toxic effect of diuretics
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the risk of adverse effect of Opioid agonists
may enhance the risk of adverse effect of Opioid agonists
may enhance the risk of adverse effect of Opioid agonists
may enhance the risk of adverse effect of Opioid agonists
may enhance the risk of adverse effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may decrease the therapeutic effect of anticholinergic agents
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may increase the toxic effect of Anticholinergic Agents
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
pegvisomant: they may decrease the therapeutic effect of opioid agonists
ramosetron: they may increase the constipating effect of opioid drugs
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
Adverse drug reactions
Frequency Defined
>10%
Vomiting
Nausea
1-10%
Skeletal muscle rigidity
Hypotension
Bradycardia
Hypertension
Respiratory depression
Tachycardia
Pregnancy warnings:
AU TGA pregnancy category: C
US FDA pregnancy category: Not Assigned
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were no enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: remifentanil
Why do we use remifentanil?
remifentanil is an Opioids (narcotic analgesics) used to treat or prevent pain during and after surgery.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
